Enliven Therapeutics (ELVN) Non-Current Assets (2019 - 2026)

Enliven Therapeutics has disclosed Non-Current Assets across 8 years of filings, most recently posting $1.7 million for Q1 2026.

• Non-Current Assets for Q1 2026 came in at $1.7 million, down 79.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $19.5 million (down 41.44% YoY), and the FY2025 annual result was $1.3 million, down 83.1% from the prior year.
• Non-Current Assets came in at $1.7 million for Q1 2026 at Enliven Therapeutics, up from $1.3 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $8.9 million in Q2 2024 to a low of $410000.0 in Q2 2022.
• The 5-year median for Non-Current Assets is $5.6 million (2022), against an average of $5.5 million.
• Across the five-year window, Non-Current Assets jumped 1199.02% in 2023 and slumped 83.1% in 2025, its largest moves.
• Enliven Therapeutics' Non-Current Assets stood at $5.5 million in 2022, then gained by 3.08% to $5.7 million in 2023, then surged by 33.54% to $7.6 million in 2024, then plunged by 83.1% to $1.3 million in 2025, then surged by 32.95% to $1.7 million in 2026.
• The last three Non-Current Assets figures came in at $1.7 million (Q1 2026), $1.3 million (Q4 2025), and $8.2 million (Q3 2025), per Business Quant data.